Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH).

Ure, Daren R; Trepanier, Daniel J; Mayo, Patrick R; Foster, Robert T

Ure, Daren R; Trepanier, Daniel J; Mayo, Patrick R; Foster, Robert T.

Affiliation

Ure DR; Hepion Pharmaceuticals Inc, Edmonton, AB, Canada.
Trepanier DJ; Hepion Pharmaceuticals Inc, Edmonton, AB, Canada.
Mayo PR; Hepion Pharmaceuticals Inc, Edmonton, AB, Canada.
Foster RT; Hepion Pharmaceuticals Inc, Edmonton, AB, Canada.

Expert Opin Investig Drugs ; 29(2): 163-178, 2020 Feb.

Article in En | MEDLINE | ID: mdl-31868526

Subject(s)

Cyclophilins/antagonists & inhibitors; Enzyme Inhibitors/therapeutic use; Non-alcoholic Fatty Liver Disease/drug therapy; Animals; Cyclophilins/metabolism; Cyclosporins/pharmacology; Cyclosporins/therapeutic use; Drug Development; Enzyme Inhibitors/pharmacology; Humans; Non-alcoholic Fatty Liver Disease/physiopathology

Key words

CRV431; Cyclophilin; NASH; collagen; cyclosporine; disease; fibrosis; hepatic; inflammation; liver; mitochondria; necrosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Cyclophilins / Enzyme Inhibitors / Non-alcoholic Fatty Liver Disease Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2020 Type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google